Ethotoin
- C
administration
- N03AB01 (WHO)
- 3-Ethyl-5-phenyl-imidazolidine-2,4-dione
- 86-35-1 Y
- 3292
- 7183
- DB00754 Y
- 3176 Y
- 46QG38NC4U
- D00708 Y
- CHEBI:4888 Y
- ChEMBL1095 Y
- DTXSID6023020
- Interactive image
- O=C2NC(c1ccccc1)C(=O)N2CC
- InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15) Y
- Key:SZQIFWWUIBRPBZ-UHFFFAOYSA-N Y
Ethotoin (previously marketed as Peganone) is an anticonvulsant drug used in the treatment of epilepsy.[1] It is a hydantoin, similar to phenytoin. It is not available in the United States.
Mechanism of action
The mechanism of action of ethotoin is similar to that of phenytoin.[citation needed]
Approval history
- 1957 Peganone was granted Food and Drug Administration (FDA) approval to Abbott Laboratories for treatment of grand mal (tonic clonic) and partial complex (psychomotor) seizures.
- 2003 Peganone was acquired from Abbott Laboratories by Ovation Pharmaceuticals (specialty pharmaceutical company who acquire underpromoted branded pharmaceutical products).
- 2018 It was announced by Recordati Rare Diseases Inc. that due to a combination of low product demand and complex manufacturing difficulties, product manufacturing, distribution and sale was being discontinued.
Indications and usage
Ethotoin is indicated for tonic-clonic and partial complex seizures.[2]
Dosing
Ethotoin is available in 250 mg tablets.[3][4] It is taken orally in 4 to 6 divided doses per day, preferably after food.
Side effects
Side effects include ataxia, visual disturbances, rash, and gastrointestinal problems.[citation needed]
Chemistry
Ethotoin is synthesized by the reaction of benzaldehyde oxynitrile (2) with urea or ammonium bicarbonate, which forms an intermediate urea derivative (3) which on acidic conditions cyclizes to 5-phenylhydantoin (4).[5] Alkylation of this product using ethyl iodide leads to the formation of ethotoin (5).
References
- ^ Schwade ED, Richards RK, Everett GM (May 1956). "Peganone, a new antiepileptic drug". Dis Nerv Syst. 17 (5): 155–8. PMID 13317788.
- ^ Shorvon, S.D.; Fish, David R.; Perucca, Emilio; Dodson, W. Edwin, eds. (2004). The Treatment of Epilepsy. Blackwell Publishing. ISBN 0-632-06046-8.
- ^ "Ethotoin". drugs.com.
- ^ "PEGANONE 250 mg Ethotoin Tablets, USP" (PDF).
- ^ A. Pinner, Chem. Ber., 21, 2324 (1888); W.J. Close, U.S. patent 2,793,157 (1946)
- v
- t
- e
modulators
CA inhibitors |
|
---|---|
Others |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III